TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Passing of Dr Sue Foden, Chair
Alderley Park, UK - 4 November 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry announces with deep sadness the sudden passing of Dr Sue Foden, the Company's Chair.
Sue was appointed as a non-executive director to TheraCryf plc (then Evgen Pharma plc) in 2015, becoming Chair in September 2023. Over the past nine years, she has been a valuable advisor and support to the leadership team and Company overall. Her passing is a great loss to the Biotech sector in the UK and beyond.
The Company will seek an additional non-executive director as soon as practicable. Our thoughts are with Sue's family during this difficult time.
Dr Huw Jones, CEO, said:
"On behalf of the Board and all my colleagues at TheraCryf I wanted to express our collective shock and sadness at the news of Sue's passing. Over the years, she showed deep passion and dedication to supporting TheraCryf and its team. Her fierce intellect, deep scientific insights, support and guidance were very important to me and she will be missed by us all."
Enquiries
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315 090
[email protected]
|
Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
|
+44 20 7220 0500
|
Vigo Consulting Rozi Morris
|
+44 207 7390 0230
[email protected]
|
About TheraCryf
TheraCryf is a clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma*, neurodevelopmental disorders, addiction, anxiety and narcolepsy* [*orphan indications].
Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. The Company has sourced know how for programmes from companies such as Shire (now Takeda).
TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and University of Connecticut.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF.
For further information, please visit: www.theracryf.com